Fluxion Biosciences has launched its Spotlight 59 Oncology Panel, a next-gen sequencing-based assay designed specifically for liquid biopsy analyses. Used in conjunction with Fluxion's IsoFlux Liquid Biopsy System the new panel allows a complete sample-to-answer assay for high sensitivity mutation detection of solid tumor cancers from blood samples, the company said. In allowing ultra-sensitive variant detection from low input quantities of DNA, the panel is also potentially useful not only for for liquid biopsy samples like circulating tumor cells or cell-free DNA, but also other challenging sample types such as FFPE.
For liquid biopsies, the high sensitivity of the panel, driven by a statistically driven bioinformatics method called ERASE-Seq, allows sensitivity to 0.1 percent allele frequency with no false positives, Fluxion said. The panel, using a 277-amplicon design based on Swift Biosciences Accel-Amplicon chemistry, covers hotspots in 59 clinically-relevant oncology-related genes, generating multiplex libraries compatible with Illumina sequencing platforms, without the need for complicated molecular barcodes.